Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: A randomized placebo-Controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4727-4735

  Bonnick, Sydney ^a   De Villiers, Tobias ^b   Odio, Alberto ^c   Palacios, Santiago ^d   Chapurlat, Roland ^e   DaSilva, Carolyn ^f   Scott, Boyd B ^f   De Tilleghem, Celine Le Bailly De ^f   Leung, Albert T ^f   Gurner, Deborah ^f  

^a Clinical Research Center of North Texas   (United States)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c Alta California Medical Group   (United States)

^d Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; CREATININE; ODANACATIB; PLACEBO;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMUR FRACTURE; FEMUR NECK; FRACTURE; FRACTURE NONUNION; HIP; HUMAN; JAW OSTEONECROSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MIDDLE AGED; MORPHEA; MULTICENTER STUDY; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; TOOTH DISEASE;

AGED; ALENDRONATE; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIUM, DIETARY; CATHEPSIN K; CHOLECALCIFEROL; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT DROPOUTS; PROTEASE INHIBITORS;

EID: 84889847492     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2020     Document Type: Article

References (36)

1. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: Its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7:447-456
2. Cusick T, Chen CM, Pennypacker BL, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012; 27:524-537
3. Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2012;27:509-523
4. Pennypacker BL, Duong le T, Masarachia PJ, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res. 2011;26:252-262
5. D'Amelio P, Grimaldi A, Di Bella S, et al. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res. 2008;23:373-379
6. D'Amelio P, Grimaldi A, Cristofaro MA, et al. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int. 2010;21: 1741-1750
7. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. J Bone Miner Res. 2010;25:2256-2265
8. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal womenwith low bone density. J Bone Miner Res. 2010;25:937-947
9. Eisman JA, BoneHG,Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Threeyear continued therapy and resolution of effect. J Bone Miner Res. 2011;26:242-251
10. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5 years of continued therapy in a phase 2 study. J Bone Miner Res. 2012; 27:2251-2258
11. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis-where do we go from here? N Engl J Med. 2012;366: 2048-2051
12. BlackDM,Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long? N Engl J Med. 2012;366:2051-2053
13. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226
15. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika. 1976; 63:655-660
16. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological). 1995;57:289-300
18. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541
19. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000; 85:4118-4124
20. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082
21. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199
22. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA. 2006;296:2927-2938
23. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19:1259-1269
24. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol. 2005;17:462-466
25. Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial. J Clin Endocrinol Metab. 2013;98: 571-580
26. Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD. Type 1 collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study. J Bone Miner Res. 2002;17:826-833
27. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: Two double-blind, randomized, placebo-controlled phase 1 studies. Clin Pharmacol Ther. 2009;86:175-182
28. Cloos PA, Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: A biological clock of protein aging with clinical potential. Biochem J. 2000;345: 473-480
29. Everts V, Korper W, Hoeben KA, et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res. 2006;21:1399-1408
30. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J. Immunochemical characterization of assay for carboxyterminal telopeptide of human type 1 collagen: loss of antigenicity by treatment with cathepsin K. Bone. 2000;26:367-373
31. Nishi Y, Atley L, Eyre DE, et al. Determination of bone markers in pycnodysostosis: Effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res. 1999;14:1902-1908
32. Rissanen JP, Suominen MI, Peng Z, Halleen JM. Secreted tartrateresistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int. 2008;82:108-115
33. Rünger TM, Adami S, Benhamou CL, et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol. 2012;66:e89-e96
34. Falgueyret JP, Desmarais S, Oballa R, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem. 2005;48:7535-7543
35. Desmarais S, Black WC, Oballa R, et al. Effect of cathepsin K inhibitor basicity on in vivo off-target activities. Mol Pharmacol. 2008;73:147-156
36. Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97:2272-2282